Lung cancer and pregnancy
https://doi.org/10.18093/0869-0189-2024-34-4-544-551
Abstract
According to world statistics, lung cancer (LC) ranks 2nd in the cancer incidence among women. Management of pregnancy-associated LC presents a clinical dilemma, as it is necessary to consider possible risks not only for the mother, but also for the fetus. The aim of the work was to study the existing literature data on diagnosis, management tactics and treatment approaches for pregnancy-associated cancer. The literature sources and presented clinical observations show disappointing findings: there was practically no response to chemotherapy (CT) in patients who received chemotherapy with platinum in combination with vinorelbine, paclitaxel, and etoposide during pregnancy and after childbirth, and a preliminary conclusion was made that change in the pharmacokinetics of chemotherapy drug may jeopardize the treatment of cancer during pregnancy. The use of surgical and radiation treatment methods depends on the individual clinical situation, stage and histotype of the tumor, as well as the gestational age. Conclusion. Thus, both diagnostic and therapeutic measures for pregnant women with LC should be personalized and performed by a special multidisciplinary team that includes a chemotherapist, radiotherapist, surgical oncologist, and obstetrician-gynecologist.
About the Authors
A. L. Chernyshova
Federal State Budgetary Institution “National Medical Research Center named after Academician E.N. Meshalkin”, Ministry of Health of the Russian Federation; Cancer Research Institute Cancer Research Institute is a Subdivision of the Federal State Budgetary Scientific Institution “Tomsk National Research Medical Center of the Russian Academy of Sciences”; Federal State Budgetary Educational Institution of Higher Education “Novosibirsk State Medical University”, Ministry of Healthcare of Russian Federation
Russian Federation
Competing Interests:
Russian Federation
Alyona L. Chernyshova - Doctor of Medicine, Professor, Russian Academy of Sciences; Director of the Institute of Oncology and Neurosurgery, Federal State Budgetary Institution “National Medical Research Center named after Academician E.N. Meshalkin”, Ministry of Health of the Russian Federation; Leading Researcher, Department of Gynecology, Cancer Research Institute Cancer Research Institute is a Subdivision of the Federal State Budgetary Scientific Institution “Tomsk National Research Medical Center of the Russian Academy of Sciences”; Professor, Department of Oncology, Federal State Budgetary Educational Institution of Higher Education “Novosibirsk State Medical University”, Ministry of Health of the Russian Federation.
Rechkunovskaya ul. 15, Novosibirsk, 630055; Savinykh ul. 12/1, Tomsk, 634028; Krasny Prospekt 52, Novosibirsk, 630091
Tel.: (913) 824-60-72
Author ID 55220758100; Reseacher ID (WOS) C-8608-2012
Competing Interests:
None
A. A. Chernyakov
Cancer Research Institute Cancer Research Institute is a Subdivision of the Federal State Budgetary Scientific Institution “Tomsk National Research Medical Center of the Russian Academy of Sciences”
Russian Federation
Competing Interests:
Russian Federation
Alexander A. Chernyakov - Resident Physician, Cancer Research Institute – Subdivision of the Federal State Budgetary Scientific Institution “Tomsk National Research Medical Center of the Russian Academy of Sciences”.
Savinykh ul. 12/1, Tomsk, 634028
Tel.: (913) 108-23-45
Author ID 1172939
Competing Interests:
None
Ju. M. Trushjuk
Cancer Research Institute Cancer Research Institute is a Subdivision of the Federal State Budgetary Scientific Institution “Tomsk National Research Medical Center of the Russian Academy of Sciences”
Russian Federation
Competing Interests:
Russian Federation
Julia M. Trushjuk - Doctor, Oncology Department No.4, Cancer Research Institute – Subdivision of the Federal State Budgetary Scientific Institution “Tomsk National Research Medical Center of the Russian Academy of Sciences”.
Savinykh ul. 12/1, Tomsk, 634028
Tel.: (953) 913-25-08
Author ID: 667545
Competing Interests:
None
O. S. Dil
Federal State Budgetary Institution “National Medical Research Center named after Academician E.N. Meshalkin”, Ministry of Health of the Russian Federation
Russian Federation
Competing Interests:
Russian Federation
Olga S. Dil - Oncologist, Institute of Oncology and Neurosurgery, Federal State Budgetary Institution “National Medical Research Center named after Academician E.N. Meshalkin”, Ministry of Health of the Russian Federation.
Rechkunovskaya ul. 15, Novosibirsk, 630055
Tel.: (913) 852-89-60
Author ID 1142135
Competing Interests:
None
A. E. Chernyshova
Federal State Budgetary Educational Institution of Higher Education “St. Petersburg State University”, Government of the Russian Federation
Russian Federation
Competing Interests:
Russian Federation
Arina E. Chernyshova - Student, Federal State Budgetary Educational Institution of Higher Education “St. Petersburg State University”, Government of the Russian Federation.
Universitetskaya Naberezhnaya 7/9, Saint-Petersburg, 199034
Tel.: (983) 239-84-74
Competing Interests:
None
References
1. Voulgaris E., Pentheroudakis G., Pavlidis N. Cancer and pregnancy: a comprehensive review. Surg. Oncol. 2011; 20 (4): e175–185. DOI: 10.1016/j.suronc.2011.06.002.
2. Pentheroudakis G., Pavlidis N. Gastrointestinal, urologic and lung malignancies during pregnancy. Recent Results Cancer Res. 2008; 178: 137–164. DOI: 10.1007/978-3-540-71274-9_13.
3. Boussios S., Han S.N., Fruscio R. et al. Lung cancer in pregnancy: report of nine cases from an international collaborative study. Lung Cancer. 2013; 82 (3): 499–505. DOI: 10.1016/j.lungcan.2013.09.002.
4. Jemal A., Siegel R., Ward E. et al. Cancer statistics, 2006. CA Cancer J. Clin. 2006; 56 (2): 106–130. DOI: 10.3322/canjclin.56.2.106.
5. Barr J.S. Placental metastases from a bronchial carcinoma. J. Obstet. Gynaecol. Br. Emp. 1953; 60 (6): 895–897. DOI: 10.1111/j.1471-0528.1953.tb07292.x.
6. Azim H.A. Jr., Peccatori F.A., Pavlidis N. Lung cancer in the pregnant woman: to treat or not to treat, that is the question. Lung Cancer. 2010; 67 (3): 251–256. DOI: 10.1016/j.lungcan.2009.10.006.
7. Hayama M., Chida M., Tamura M. et al. Unexpected rapid growth of estrogen receptor positive lung cancer during pregnancy. Ann. Thorac. Cardiovasc. Surg. 2014; 20 (4): 325–328. DOI: 10.5761/atcs.cr.12.01934.
8. Sarıman N., Levent E., Yener N.A. et al. Lung cancer and pregnancy. Lung Cancer. 2013; 79 (3): 321–323. DOI: 10.1016/j.lungcan.2012.11.014.
9. Ceauşu M., Hostiuc S., Sajin M. et al. Gestational lung adenocarcinoma: case report. Int. J. Surg. Pathol. 2014; 22 (7): 663–666. DOI: 10.1177/1066896914531816.
10. Kim J.W., Kim J.S., Cho J.Y., Lee D.H. Successful video-assisted thoracoscopic lobectomy in a pregnant woman with lung cancer. Lung Cancer. 2014; 85 (2): 331–334. DOI: 10.1016/j.lungcan.2014.05.022.
11. Neves I., Mota P.C., Hespanhol V.P. Lung cancer during pregnancy: an unusual case. Rev. Port. Pneumol. 2014; 20 (1): 46–49. DOI: 10.1016/j.rppneu.2013.06.005.
12. Gil S., Goetgheluck J., Paci A. et al. Efficacy and safety of gefitinib during pregnancy: case report and literature review. Lung Cancer. 2014; 85 (3): 481–484. DOI: 10.1016/j.lungcan.2014.06.003.
13. Wang A., Kubo J., Luo J. et al. Active and passive smoking in relation to lung cancer incidence in the Women's Health Initiative Observational study prospective cohort. Ann. Oncol. 2015; 26 (1): 221–230. DOI: 10.1093/annonc/mdu470.
14. Lortet-Tieulent J., Soerjomataram I., Ferlay J. et al. International trends in lung cancer incidence by histological subtype: adenocarcinoma stabilizing in men but still increasing in women. Lung Cancer. 2014; 84 (1): 13–22. DOI: 10.1016/j.lungcan.2014.01.009.
15. Azim H.A. Jr., Peccatori F.A., Pavlidis N. Treatment of the pregnant mother with cancer: a systematic review on the use of cytotoxic, endocrine, targeted agents and immunotherapy during pregnancy. Part I: Solid tumors. Cancer Treat. Rev. 2010; 36 (2): 101–109. DOI: 10.1016/j.ctrv.2009.11.007.
16. Pavlidis N., Peccatori F.A., Lofts F., Greco A.F. Cancer of unknown primary during pregnancy: an exceptionally rare coexistence. Anticancer Res. 2015; 35 (1): 575–579. Available at: https://ar.iiarjournals.org/content/35/1/575
17. Pentheroudakis G., Orecchia R., Hoekstra H.J. et al. Cancer, fertility and pregnancy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2010; 21 (Suppl. 5): v266–273. DOI: 10.1093/annonc/mdq198.
18. Olsen J., Pedersen L.H. Reproductive health indicators and fetal medicine – many things will change. Scand. J. Work Environ. Health. 2016; 42 (6): 561–562. DOI: 10.5271/sjweh.3596.
19. Soberanis Pina P., Lara-Mej´ıa L., Matias-Cruz V. et al. Case report: Osimertinib administration during pregnancy in a woman with advanced EGFR-mutant non-small cell lung cancer. Front. Oncol. 2023; 13:1108124. DOI: 10.3389/fonc.2023.1108124.
20. Sung H., Ferlay J., Siegel R.L. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2021; 71 (3): 209–249. DOI: 10.3322/caac.21660.
21. Arrieta O., Zatarain-Barrón Z.L., Aldaco F. et al. Lung cancer in Mexico. J. Thorac. Oncol. 2019; 14 (10):1695–700. DOI: 10.1016/j.jtho.2019.05.018.
22. Bellido C., Barbero P., Forcén L. et al. Lung adenocarcinoma during pregnancy: clinical case and literature review. J. Maternal. Fetal Neonatal Med. 2019; 32 (19): 3300–3302. DOI: 10.1080/14767058.2018.1461830.
23. Passaro A., Leighl N., Blackhall F et al. ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer. Ann. Oncol. 2022. 33 (5): 466–487. DOI: 10.1016/j.annonc.2022.02.003.
24. Rosell R., Cardona A.F., Arrieta O. et al. Coregulation of pathways in lung cancer patients with EGFR mutation: therapeutic opportunities. Br. J. Cancer. 2021; 125: 1602–1611. DOI: 10.1038/s41416-021-01519-2.
25. Corrales-Rodrıguez L., Arrieta O., Mas L. et al. An international epidemiological analysis of young patients with nonsmall cell lung cancer (AduJov-CLICaP). Lung Cancer. 2017; 113: 30–36. DOI: 10.1016/j.lungcan.2017.08.022.
26. Dagogo-Jack I., Gainor J.F., Porter R.L. et al. Clinicopathologic features of NSCLC diagnosed during pregnancy or the peripartum period in the era of molecular genotyping. J. Thorac. Oncol. 2016; 11 (9): 1522–1528. DOI: 10.1016/j.jtho.2016.05.031.
27. Jin J., Wu X., Yin J. et al. Identification of genetic mutations in cancer: Challenge and opportunity in the new era of targeted therapy. Front. Oncol. 2019; 9: 263. DOI: 10.3389/FONC.2019.00263.
28. Kooijman J.J., van Riel W.E., Dylus J. et al. Comparative kinase and cancer cell panel profiling of kinase inhibitors approved for clinical use from 2018 to 2020. Front. Oncol. 2022; 12: 953013. DOI: 10.3389/FONC.2022.953013.
29. Qi Y., Xia X., Shao L. et al. An updated network metaanalysis of EGFR-TKIs and combination therapy in the first-line treatment of advanced EGFR mutation positive non-small cell lung cancer. Front. Oncol. 2022; 12: 616546. DOI: 10.3389/FONC.2022.616546.
30. Rayego-Mateos S., Rodrigues-Diez R., Morgado-Pascual J.L. et al. Role of epidermal growth factor receptor (EGFR) and its ligands in kidney inflammation and damage. Mediators Inflamm. 2018; 2018: 8739473. DOI: 10.1155/2018/8739473.
31. Robinson A.A., Watson W.J., Leslie K.K. Targeted treatment using monoclonal antibodies and tyrosine-kinase inhibitors in pregnancy. Lancet Oncol. 2007; 8 (8): 738–743. DOI: 10.1016/S1470-2045(07)70242-5.
32. Boudy A.S., Grausz N., Selleret L. et al. Use of tyrosine kinase inhibitors during pregnancy for oncogenic-driven advanced non-small cell lung carcinoma. Lung Cancer. 2021; 161: 68–75. DOI: 10.1016/j.lungcan.2021.09.001.
33. Kim Y., Lee S.H., Ahn J.S. et al. Efficacy and safety of afatinib for EGFR-mutant non-small cell lung cancer, compared with gefitinib or erlotinib. Cancer Res. Treat. 2019; 51 (2): 502–509. DOI: 10.4143/CRT.2018.117.
34. Orefice R. Immunology and the immunological response in pregnancy. Best Pract. Res. Clin. Obstetю Gynaecol. 2021. 76: 3–12. DOI: 10.1016/J.BPOBGYN.2020.07.013.
35. Kareva I. Immune suppression in pregnancy and cancer: parallels and insights. Transl. Oncol. 2020; 13 (7): 100759. DOI: 10.1016/J.TRANON.2020.100759.
36. Rodriguez-Lara V., Hernandez-Martinez J.M., Arrieta O. Influence of estrogen in non-small cell lung cancer and its clinical implications. J. Thorac Dis. 2018; 10 (1): 482–497. DOI: 10.21037/JTD.2017.12.61.
37. Kuznetsov PA, Olenev AS, Dzhokhadze LS, Seliverstova OM. [Impact of ionizing radiation on the fetus]. Rossiyskiy vestnik akushera-ginekologa. 2018; 18 (5): 32–35. DOI: 10.17116/rosakush20181805132 (in Russian).
38. Rosell R., Cardona A.F., Arrieta O. et al. Coregulation of pathways in lung cancer patients with EGFR mutation: therapeutic opportunities. Br. J. Cancer. 2021; 125 (12): 1602–1611. DOI: 10.1038/s41416-021-01519-2.
Supplementary files
Review
For citations:
Chernyshova A.L., Chernyakov A.A., Trushjuk J.M., Dil O.S., Chernyshova A.E. Lung cancer and pregnancy. PULMONOLOGIYA. 2024;34(4):544-551. (In Russ.) https://doi.org/10.18093/0869-0189-2024-34-4-544-551
Views:
394
Email this article 